S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

DURECT Stock Forecast, Price & News

-0.05 (-8.64%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
23.47 million shs
Average Volume
1.02 million shs
Market Capitalization
$120.46 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Stock Forecast (MarketRank)

Overall MarketRank

1.58 out of 5 stars

Medical Sector

974th out of 1,417 stocks

Pharmaceutical Preparations Industry

484th out of 675 stocks

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -


DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DRRX Stock News Headlines

Short Interest in DURECT Co. (NASDAQ:DRRX) Declines By 14.5%
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Net Income
$-36.26 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$13.98 million
Book Value
$0.25 per share


Free Float
Market Cap
$120.46 million

DURECT Frequently Asked Questions

Should I buy or sell DURECT stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DURECT stock.
View analyst ratings for DURECT
or view top-rated stocks.

How has DURECT's stock price performed in 2022?

DURECT's stock was trading at $0.9859 on January 1st, 2022. Since then, DRRX shares have decreased by 46.4% and is now trading at $0.5289.
View the best growth stocks for 2022 here

Are investors shorting DURECT?

DURECT saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 11,290,000 shares, a decrease of 14.5% from the May 15th total of 13,200,000 shares. Based on an average trading volume of 917,400 shares, the short-interest ratio is currently 12.3 days. Approximately 5.0% of the shares of the company are sold short.
View DURECT's Short Interest

When is DURECT's next earnings date?

DURECT is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for DURECT

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) posted its earnings results on Wednesday, May, 4th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). The specialty pharmaceutical company had revenue of $1.92 million for the quarter, compared to analysts' expectations of $2.43 million. DURECT had a negative net margin of 270.27% and a negative trailing twelve-month return on equity of 60.89%. During the same quarter last year, the firm posted ($0.05) earnings per share.
View DURECT's earnings history

Who are DURECT's key executives?

DURECT's management team includes the following people:
  • Dr. James E. Brown D.V.M., Co-Founder, CEO, Pres & Director (Age 65, Pay $859.68k)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 65, Pay $436.99k)
  • Dr. Norman L. Sussman M.D., Chief Medical Officer (Age 69, Pay $570.32k)
  • Ms. Jian Li M.B.A., Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec. (Age 52)
  • Dr. Andrew R. Miksztal, VP of Pharmaceutical R&D and Principal Scientist
  • Mr. Steve Helmer J.D., VP & Chief Patent Counsel
  • Dr. WeiQi Lin, Exec. VP of R&D and Principal Scientist
  • Dr. Su Il Yum Ph.D., Exec. Officer (Age 83)

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.06%), Ingalls & Snyder LLC (3.18%), State Street Corp (1.75%), CM Management LLC (1.55%), Renaissance Technologies LLC (1.54%) and Beirne Wealth Consulting Services LLC (1.21%). Company insiders that own DURECT stock include Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito.
View institutional ownership trends for DURECT

Which institutional investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Ingalls & Snyder LLC, Goldman Sachs Group Inc., and Simplex Trading LLC. Company insiders that have sold DURECT company stock in the last two years include Judy R Joice, and Lp Bleichroeder.
View insider buying and selling activity for DURECT
or view top insider-selling stocks.

Which institutional investors are buying DURECT stock?

DRRX stock was bought by a variety of institutional investors in the last quarter, including CM Management LLC, Renaissance Technologies LLC, Beirne Wealth Consulting Services LLC, Connor Clark & Lunn Investment Management Ltd., Eqis Capital Management Inc., Gagnon Securities LLC, State Street Corp, and Tobias Financial Advisors Inc.. Company insiders that have bought DURECT stock in the last two years include Gail M Farfel, Judith J Robertson, Mohammad Azab, and Simon X Benito.
View insider buying and selling activity for DURECT
or or view top insider-buying stocks.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $0.53.

How much money does DURECT make?

DURECT (NASDAQ:DRRX) has a market capitalization of $120.46 million and generates $13.98 million in revenue each year. The specialty pharmaceutical company earns $-36.26 million in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does DURECT have?

DURECT employs 79 workers across the globe.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for DURECT is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at [email protected], or via fax at 408-777-3577.

This page (NASDAQ:DRRX) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.